A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics.
Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners.
The company’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF). It was developed by Nevan Krogan, Director of QBI and a co-founder and Chief Executive Officer of Rezo.
Kevan Shokat, the inventor of leading drugs targeting KRAS, is also a co-founder as well as a Professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI).
Rezo’s Sequence to Systems to Drugs (SSD) platform integrates data from proteomics, genetics, structural biology, and chemical biology approaches using computational methods to create comprehensive maps of molecular disease networks.
The disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.
The company intends to focus initially on solid tumor oncology guided by mutation and allele-specific biomarkers.
Dr Krogan said: “By integrating technological advances and leveraging complementary strengths between industry and academia, we believe there is an untapped opportunity to map and target the interactions that go awry in disease.”
